Publicacións en colaboración con investigadores/as de Novartis (Sweden) (3)

2023

  1. Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 3, pp. 1046-1055

2022

  1. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 1, pp. 106-115

2021

  1. Secukinumab in patients with psoriatic arthritis and axial manifestations: Results from the double-blind, randomised, phase 3 MAXIMISE trial

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 5, pp. 582-590